Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
letter
. 1990;30(Suppl 1):112S–114S. doi: 10.1111/j.1365-2125.1990.tb05478.x

Differential regulation of human cardiac β-adrenergic and muscarinic receptors by chronic β-adrenoceptor antagonist treatment

S Motomura, N M Deighton, H-R Zerkowski, M Khamssi, O-E Brodde
PMCID: PMC1368108  PMID: 1980074

Abstract

In patients undergoing coronary artery bypass grafting chronic β1-adrenoceptor antagonist treatment increased right atrial β1-adrenoceptor number, did not affect β2-adrenoceptor number and decreased muscarinic M2-receptor number. Concomitantly, the M2-receptor-mediated negative inotropic effect of carbachol was reduced, while the β1-adrenoceptor-mediated positive inotropic effect of noradrenaline was not altered. The β2-adrenoceptor mediated positive inotropic effect of procaterol, however, was markedly enhanced. We conclude that chronic β1-adrenoceptor antagonist treatment increases β1-adrenoceptor number, sensitizes β2-adrenoceptor function and desensitizes M2-receptor function in the human heart.

Keywords: β1- and β2-adrenoceptors in the human heart, muscarinic M2-receptors in the human heart, chronic β1-adrenoceptor antagonist treatment

Full text

PDF
112S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brodde O. E., Wang X. L. Beta-adrenoceptor changes in blood lymphocytes and altered drug responsiveness. Ann Clin Res. 1988;20(5):311–323. [PubMed] [Google Scholar]
  2. Brodde O. E., Zerkowski H. R., Doetsch N., Motomura S., Khamssi M., Michel M. C. Myocardial beta-adrenoceptor changes in heart failure: concomitant reduction in beta 1- and beta 2-adrenoceptor function related to the degree of heart failure in patients with mitral valve disease. J Am Coll Cardiol. 1989 Aug;14(2):323–331. doi: 10.1016/0735-1097(89)90181-2. [DOI] [PubMed] [Google Scholar]
  3. Deighton N. M., Motomura S., Borquez D., Zerkowski H. R., Doetsch N., Brodde O. E. Muscarinic cholinoceptors in the human heart: demonstration, subclassification, and distribution. Naunyn Schmiedebergs Arch Pharmacol. 1990 Jan-Feb;341(1-2):14–21. doi: 10.1007/BF00195052. [DOI] [PubMed] [Google Scholar]
  4. Kaumann A. J., Hall J. A., Murray K. J., Wells F. C., Brown M. J. A comparison of the effects of adrenaline and noradrenaline on human heart: the role of beta 1- and beta 2-adrenoceptors in the stimulation of adenylate cyclase and contractile force. Eur Heart J. 1989 Jun;10 (Suppl B):29–37. doi: 10.1093/eurheartj/10.suppl_b.29. [DOI] [PubMed] [Google Scholar]
  5. McDevitt D. G. Adrenoceptor blocking drugs: clinical pharmacology and therapeutic use. Drugs. 1979 Apr;17(4):267–288. doi: 10.2165/00003495-197917040-00002. [DOI] [PubMed] [Google Scholar]
  6. Michel M. C., Pingsmann A., Beckeringh J. J., Zerkowski H. R., Doetsch N., Brodde O. E. Selective regulation of beta 1- and beta 2-adrenoceptors in the human heart by chronic beta-adrenoceptor antagonist treatment. Br J Pharmacol. 1988 Jul;94(3):685–692. doi: 10.1111/j.1476-5381.1988.tb11576.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Prichard B. N., Tomlinson B., Walden R. J., Bhattacharjee P. The beta-adrenergic blockade withdrawal phenomenon. J Cardiovasc Pharmacol. 1983;5 (Suppl 1):S56–S62. doi: 10.1097/00005344-198300051-00009. [DOI] [PubMed] [Google Scholar]
  8. Reithmann C., Gierschik P., Sidiropoulos D., Werdan K., Jakobs K. H. Mechanism of noradrenaline-induced heterologous desensitization of adenylate cyclase stimulation in rat heart muscle cells: increase in the level of inhibitory G-protein alpha-subunits. Eur J Pharmacol. 1989 Aug 15;172(3):211–221. doi: 10.1016/0922-4106(89)90051-5. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES